Puangrat Yongvanit Selected Research

Digestive System Diseases

1/2020	Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort.
1/2019	Evaluation of a short term effect of praziquantel treatment in opisthorchiasis-induced hepatobiliary inflammation by urinary 8-oxodG.
1/2018	Elevated Levels of Urinary 8-oxodG Correlate with Persistent Periductal Fibrosis after Praziquantel Treatment in Chronic Opisthorchiasis.
5/2014	Risk biomarkers for assessment and chemoprevention of liver fluke-associated cholangiocarcinoma.
4/2013	Oxidized alpha-1 antitrypsin as a predictive risk marker of opisthorchiasis-associated cholangiocarcinoma.
8/2012	Plasma hydroxyproline, MMP-7 and collagen I as novel predictive risk markers of hepatobiliary disease-associated cholangiocarcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Puangrat Yongvanit Research Topics

Disease

71	Cholangiocarcinoma 10/2021 - 09/2003
50	Neoplasms (Cancer) 01/2019 - 08/2005
34	Infections 01/2019 - 09/2003
25	Opisthorchiasis 01/2019 - 07/2008
24	Inflammation (Inflammations) 01/2020 - 09/2003
23	Carcinogenesis 01/2018 - 09/2003
14	Fibrosis (Cirrhosis) 01/2019 - 06/2009
13	Neoplasm Metastasis (Metastasis) 11/2017 - 03/2010
6	Digestive System Diseases 01/2020 - 08/2012
3	Body Weight (Weight, Body) 10/2021 - 03/2017
3	Hepatocellular Carcinoma (Hepatoma) 12/2018 - 01/2012
3	Parasitic Diseases (Parasitic Disease) 08/2017 - 05/2006
2	Persistent Infection 01/2017 - 09/2003
2	Reinfection 01/2017 - 05/2012
2	Hypoxia (Hypoxemia) 01/2015 - 08/2005
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2013 - 06/2012
2	Overweight 06/2012 - 11/2011
2	Thiamine Deficiency 11/2007 - 05/2006
1	Pathologic Constriction (Stenosis) 01/2020
1	Liver Diseases (Liver Disease) 01/2020

Drug/Important Bio-Agent (IBA)

22	Proteins (Proteins, Gene)FDA Link 01/2018 - 09/2005
16	Biomarkers (Surrogate Marker)IBA 01/2020 - 09/2005
10	Praziquantel (Biltricide)FDA Link 01/2019 - 09/2006
9	8-Hydroxy-2'-DeoxyguanosineIBA 01/2019 - 09/2003
8	EnzymesIBA 02/2017 - 12/2010
8	Dimethylnitrosamine (Nitrosodimethylamine)IBA 11/2015 - 05/2006
8	Messenger RNA (mRNA)IBA 12/2014 - 06/2009
6	AntioxidantsIBA 01/2018 - 01/2007
6	OxysterolsIBA 12/2014 - 03/2011
6	8-nitroguanineIBA 12/2013 - 09/2003
5	AntigensIBA 01/2019 - 08/2011
5	Cadherins (E-Cadherin)IBA 01/2018 - 12/2012
5	CytokinesIBA 01/2017 - 06/2009
4	Pharmaceutical PreparationsIBA 10/2021 - 03/2012
4	xanthohumolIBA 05/2020 - 01/2012
4	Bile Acids and Salts (Bile Acids)IBA 01/2020 - 01/2012
4	CurcuminIBA 01/2016 - 10/2009
4	Oxygen (Dioxygen)IBA 12/2014 - 09/2003
4	Matrix Metalloproteinases (MMPs)IBA 08/2012 - 06/2009
3	Biological ProductsIBA 10/2021 - 05/2012
3	Transferrin (beta 2 Transferrin)IBA 01/2019 - 04/2012
3	Immunoglobulin G (IgG)IBA 01/2018 - 08/2011
3	CarcinogensIBA 01/2017 - 09/2006
3	Indicators and Reagents (Reagents)IBA 12/2014 - 04/2013
3	CollagenIBA 08/2012 - 06/2009
3	Hydroxyproline (4 Hydroxyproline)IBA 08/2012 - 06/2009
3	Cyclin D1IBA 04/2012 - 10/2009
2	Amino Acids FDA Link 01/2020 - 03/2017
2	LipidsIBA 01/2020 - 10/2013
2	Blood Proteins (Serum Proteins)IBA 01/2019 - 01/2012
2	ResveratrolIBA 10/2018 - 01/2018
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 08/2018 - 12/2013
2	Gemcitabine FDA Link 01/2018 - 01/2018
2	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 01/2018 - 08/2017
2	IronIBA 01/2018 - 07/2017
2	Matrix Metalloproteinase 9 (Gelatinase B)IBA 11/2017 - 01/2017
2	MicroRNAs (MicroRNA)IBA 08/2017 - 12/2014
2	Amino Acid Transport Systems (Amino Acid Transporter)IBA 08/2017 - 03/2017
2	ImmunosorbentsIBA 01/2017 - 01/2015
2	16S Ribosomal RNAIBA 06/2016 - 01/2016
2	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 01/2012
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2015 - 07/2011
2	NitrogenIBA 12/2014 - 09/2003
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 12/2014 - 04/2012
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2014 - 12/2012
2	Dinoprostone (PGE2)FDA Link 08/2014 - 01/2012
2	CateninsIBA 06/2014 - 01/2014
2	CholesterolIBA 01/2014 - 03/2012
2	Transcription Factors (Transcription Factor)IBA 01/2014 - 12/2012
2	Superoxide DismutaseIBA 12/2013 - 05/2012
2	Sodium Glutamate (Accent)IBA 01/2013 - 06/2012
2	Platelet-Derived Growth FactorIBA 10/2012 - 03/2012
2	Tissue Inhibitor of Metalloproteinase-2IBA 08/2012 - 06/2009
2	NF-kappa B (NF-kB)IBA 05/2012 - 09/2006
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 03/2012 - 08/2004
2	Immunoglobulin A (IgA)IBA 03/2012 - 08/2011
2	AntibodiesIBA 03/2012 - 08/2011
2	NitrosaminesIBA 03/2012 - 07/2011
2	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 03/2012 - 03/2012
2	Tyrosine (L-Tyrosine)FDA Link 01/2012 - 09/2005
2	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 01/2012 - 07/2011
2	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2012 - 07/2011
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 12/2010 - 08/2004
2	Antiparasitic Agents (Antiparasitics)IBA 01/2010 - 03/2008
2	Thiamine (Aneurin)FDA Link 11/2007 - 05/2006
2	Nucleic AcidsIBA 08/2004 - 09/2003
1	UridineIBA 10/2021
1	PseudouridineIBA 10/2021
1	XenobioticsIBA 10/2021
1	NucleotidesIBA 10/2021
1	7-methylguanineIBA 10/2021
1	FlavonoidsIBA 05/2020
1	SteroidsIBA 01/2020
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2020
1	Phenylalanine (L-Phenylalanine)FDA Link 01/2020
1	Polysaccharides (Glycans)IBA 01/2019
1	artenimol (dihydroartemisinin)IBA 12/2018
1	NVP-BKM120IBA 08/2018

Therapy/Procedure

10	Therapeutics 01/2018 - 10/2009
2	Drug Therapy (Chemotherapy) 01/2017 - 07/2016